NCT07833098尚未招募2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase II Clinical Study to Evaluate the Efficacy and Safety of VB19055 in Participants With Hypertension (Including Resistant Hypertension) Whose Blood Pressure Remains Uncontrolled Despite Treatment With Two or More Antihypertensive Medications
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.24 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2026年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 240
- 试验地点
- 24
- 主要终点
- Change from baseline in seated clinic systolic blood pressure at Week 12.
研究概览
简要总结
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).
详细描述
This study is a multicenter, randomized, double-blind, placebo parallel-controlled, dose-ranging Phase II clinical trial designed to evaluate the efficacy and safety of 12-week treatment with VB19055 in trial participants with hypertension (including resistant hypertension) whose blood pressure remains uncontrolled despite treatment with two or more antihypertensive medications, and to explore the dosing regimen for confirmatory studies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult male and female aged ≥18 years;
- •Mean seated systolic blood pressure (SBP) ≥140 mmHg and <170 mmHg at screening, and SBP ≥135 mmHg and <170 mmHg at randomization (Mean seated SBP/DBP is defined as the average of 3 seated SBP/DBP measurements obtained by automated office blood pressure measurement at a single clinic visit. If the trial participant has not taken routine antihypertensive medication prior to the visit, a repeat mean blood pressure measurement may be performed within 2 days after dosing.)
- •Meet at least one of the following two criteria:
- •Uncontrolled hypertension: At screening and randomization, as judged by the investigator, stably taking antihypertensive medications of two different therapeutic classes at maximum tolerated dose for ≥4 weeks (at least one must be a non-potassium-sparing diuretic). Beta-blockers used for other indications (e.g., migraine, heart failure, coronary artery disease) shall not count toward antihypertensive medications for eligibility;
- •Resistant hypertension: At screening and randomization, as judged by the investigator, stably taking antihypertensive medications of ≥3 different therapeutic classes at maximum tolerated dose for ≥4 weeks (at least one must be a non-potassium-sparing diuretic). Beta-blockers used for other indications (e.g., migraine, heart failure, coronary artery disease) shall not count toward antihypertensive medications for eligibility.
- •Serum potassium (K⁺) ≥3.5 and <5.0 mmol/L at screening (local laboratory);
- •Morning (08:00 ± 2 hours) serum cortisol >3 µg/dL (local or central laboratory);
- •Female participants of childbearing potential agree to no pregnancy plans and use highly effective contraception from ICF signing until 30 days after last dose; male participants agree to no fertility plans and use highly effective contraception from ICF signing until 90 days after last dose (see Appendix 2 for details);
- •Voluntarily participate in this clinical study and have the capacity to sign the informed consent form.
排除标准
- •Known causes of secondary hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism/hypothyroidism, hyperparathyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation, or obstructive sleep apnea syndrome being treated with continuous positive airway pressure (CPAP) (participants with primary aldosteronism may be considered for enrollment unless adrenalectomy is planned before study completion);
- •Have undergone coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) or any major surgery (e.g., valve replacement, peripheral artery bypass surgery) within 6 months prior to ICF signing, or plan to undergo such procedures during the study;
- •Arrhythmia requiring treatment or left bundle branch block at screening;
- •Known chronic permanent atrial fibrillation;
- •New York Heart Association (NYHA) Class III or IV chronic heart failure at screening;
- •Glycated hemoglobin (HbA1c) >9.5% at screening;
- •Adrenal insufficiency diagnosed within 6 months prior to ICF signing;
- •Any of the following abnormal laboratory/physical examination findings at screening:
- •Serum sodium <135 mmol/L;
- •Mean seated SBP ≥170 mmHg or mean seated DBP ≥110 mmHg;
- •Aspartate aminotransferase (AST) >3.0 × upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3.0 × ULN;
- •Total bilirubin >2.0 × ULN, unless the participant has a history of Gilbert's syndrome;
- •Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m²;
- •Body mass index (BMI) <18 kg/m² or ≥45 kg/m²;
- •Any of the following ECG abnormalities: heart rate <45 bpm or >110 bpm; QT interval corrected by Fridericia's formula (QTcF) >470 ms;
- •Clinically significant abnormal chest imaging (chest X-ray or computed tomography [CT]) assessed by the investigator as posing a safety risk;
- •Positive hepatitis B surface antigen (HBsAg) with possible viral replication (positive HBV DNA) as judged by the investigator based on further testing, or positive anti-hepatitis C virus (HCV) antibody, or positive human immunodeficiency virus (HIV) antibody.
研究组 & 干预措施
VB19055 Arm A
Experimental
干预措施: VB19055 Dose A QD (Drug)
VB19055 Arm B
Experimental
干预措施: VB19055 Dose B QD (Drug)
VB19055 Arm C
Experimental
干预措施: VB19055 Dose C QD (Drug)
VB19055 placebo QD
Placebo Comparator
干预措施: VB19055 placebo QD (Drug)
结局指标
主要结局
Change from baseline in seated clinic systolic blood pressure at Week 12.
时间窗: at the end of the 12-week treatment period
次要结局
- Adverse events, including treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), TEAEs leading to permanent discontinuation, adverse events of special interest (AESI), etc.(12-week treatment period)
- Change from baseline in seated clinic diastolic blood pressure at Week 12(at the end of the 12-week treatment period)
- Percentage of participants with a seated blood pressure of less than 140/90 mmHg at the end of the 12-week treatment period(at the end of the 12-week treatment period)
- Percentage of participants with a seated blood pressure of less than 130/80 mmHg at the end of the 12-week treatment period(at the end of the 12-week treatment period)
- Change from baseline in mean SBP and DBP, daytime SBP and DBP, nighttime SBP and DBP, and trough-to-peak ratio (T/P) of SBP and DBP by ambulatory blood pressure monitoring (ABPM) at Week 12(at the end of the 12-week treatment period)
研究者
研究点 (24)
Loading locations...
相似试验
尚未招募
2 期
A Study of AC-101 Tablets in Patients With Ulcerative ColitisUlcerative Colitis (UC)NCT07755241Accro Bioscience (Suzhou) Limited153
尚未招募
2 期
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)Chronic Spontaneous Urticaria (CSU)Chronic Idiopathic UrticariaNCT07766499Calixis Inc.81
Unknown
不适用
A study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis.Other interstitial pulmonary diseases with fibrosis,CTRI/2024/11/077147Pliant Therapeutics Inc1,113
招募中
2 期
Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney InjuryAcute Kidney InjuryNCT07625553River 2 Renal Corp.430
尚未招募
2 期
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic DermatitisAtopic Dermatitis (AD)NCT07784816Hangzhou Highlightll Pharmaceutical Co., Ltd390